Child with Rare Disorder to be Treated Free

Published: 03rd February 2016 06:21 AM  |   Last Updated: 03rd February 2016 06:21 AM   |  A+A-

CHENNAI: Parents of four-year-old Kaviyan Senthil, who is suffering from a rare genetic metabolic disease, heaved a sigh of relief after the State government recommended an expensive enzyme replacement therapy for the child, free of cost.

The Lysosomal Storage Disorders Support Society, India (LSDSS), in May 2014, filed an application with the government of Tamil Nadu demanding free treatment to patients in the state suffering from Gaucher, Pompe and Mucopolysaccharidoses (MPS), all genetic metabolic disorders.

Following this, the government directed the Institute of Child Health, Egmore to provide the treatment.

The Institute then constituted a medical board that recommended treatment- Enzyme Replacement Therapy to Kaviyan Senthil, who is suffering from MPS-I (Hurler Syndrome).

MPS-I is a very rare genetic metabolic disease caused by an inborn enzyme deficiency which leads to significant enlargement of the heart, weakness of heart muscles, respiratory distress, breathing complications and growth retardation.

Manjit Singh, president of Lysosomal Storage Disorders Support Society, India (LSDSS) said that there  are 598 LSD affected children from across India with the society, of which 182 are from Tamil Nadu. 30 children had died due to non availability of treatment last year, added Manjit Singh.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp